It has been previously demonstrated that signals that activate normal cells can lead to inhibition of neoplastic cells by inducing activation-induced cell death. Therefore, inhibition of neoplastic cell growth can be achieved through the use of CD40 stimulation. The invention discloses monoclonal antibodies to CD40, CD40 ligands, and combinations thereof. Oligomeric forms of CD40 ligands and fusion protein ligands are also disclosed. This invention is jointly owned by the National Institutes of Health and Immunex Corporation.
All fields of use are available for licensing.
This vectorette unit is an oligonucleotide 53 bases in length, and has a unique sequence which is not found in the human genome. This method appears to represent four key advantages over existing sequencing methods. First, the sequence of a long fragment of DNA can be obtained far more rapidly than is currently possible. Second, as multiple cloning steps are not necessary, it is easier to perform. Third, a much smaller amount of DNA is needed for this method than is necessary when using currently available sequencing techniques.